Premium
Acadia Pharmaceuticals Inc (ACAD)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks t... Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. Show more
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a...
Acadia Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As...
– Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.73 | 3.92895586652 | 18.58 | 19.6 | 18.03 | 1292483 | 18.58912184 | CS |
| 4 | 1.92 | 11.0408280621 | 17.39 | 19.6 | 16.61 | 1737703 | 17.88838882 | CS |
| 12 | 1.18 | 6.50854936569 | 18.13 | 19.6 | 15.66 | 2510818 | 17.74118384 | CS |
| 26 | 1.39 | 7.75669642857 | 17.92 | 19.6 | 14.15 | 1955338 | 16.86526327 | CS |
| 52 | -5.69 | -22.76 | 25 | 26.78 | 14.15 | 1876724 | 17.68301702 | CS |
| 156 | -4.29 | -18.1779661017 | 23.6 | 33.99 | 12.24 | 1752693 | 19.89098605 | CS |
| 260 | -22.76 | -54.1003090088 | 42.07 | 58.72 | 12.24 | 1664708 | 24.69262402 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
